Additionally, we found that reduced extent of proliferation rate induced by cisplatin treatment in A549/DDP cells was significantly greater than in A549 cells after knockdown of FANCF or FANCL (Fig. 4a and 6a, Table 1), suggesting that knockdown of FANCF or FANCL can reverse resistance of cisplatin-resistant lung cancer cells to cisplatin, whereas the knockdown of the two genes in cisplatin-sensitive lung cancer cells only moderately increase sensitivity to cisplatin. The gene discussed is FANCL; the disease is lung carcinoma.